A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation. - Fujii, Takeo; Cimino‐Mathews, Ashley; Lipkowitz, Stanley; Lee, Min‐Jung; Nair, Jayakumar; Solarz, Britanny Brooke; Zimmer, Alexandra; Redd, Bernadette; Levy, Elliot B.; Rastogi, Shraddha; Sato, Nahoko; McCoy, Ann; et al. (Cancer Medicine, 2025)